WO2022090807A2

WO2022090807A2 - Cannabigerol and tetrahydrocannabivarin antidote formulations and methods of using the same

Info

Publication number: WO2022090807A2
Application number: PCT/IB2021/000776
Authority: WO
Inventors: Mark Scott; David WEINKAUF
Original assignee: Next Level Health Sciences Inc.
Priority date: 2020-10-30
Filing date: 2021-11-01
Publication date: 2022-05-05
Also published as: WO2022090807A3

Abstract

Antidote compositions are disclosed that contain cannabigerol (CBG) and/or tetrahydrocannabivarin (THCV) that can be used to offset THC-induced biological effects, particularly for THC-containing edibles.

Description

CANNABIGEROL AND TETRAHYDROCANNABIVARIN ANTIDOTE

FORMULATIONS AND METHODS OF USING THE SAME

CROSS REFERENCE TO RELATED APPLICATIONS

[001] This application claims priority to, and the benefit of, U.S. Provisional

Patent Application Serial No. 63/108,008 filed on October 30, 2020 entitled

“CANNABIGEROL AND TETRAHYDROCANN ABIVARIN ANTIDOTE

FORMULATIONS AND METHODS OF USING THE SAME”, the disclosure of which is hereby incorporated by reference in their entirety.

FIELD

[002] The present disclosure relates to compositions containing cannabigerol (CBG) and/or tetrahydrocannabivarin (THCV), more particularly, to CBG-containing and/or THCV-containing antidote compositions that can be used to offset THC- induced biological effects.

BACKGROUND

[003] Tetrahydrocannabinol (THC) is one of the many cannabinoids found in cannabis. THC is a psychoactive compound responsible for certain intoxicating effects experienced by users of cannabis, including certain undesirable psychological reactions.

[004] The effects of THC are dose-dependent and may be influenced by a number of factors including, but not limited to, the cultivation conditions of cannabis, and the mode of administration. The reactions caused by THC result from its ability' to bind to and activate certain cannabinoid receptors, such as cannabinoid receptor type 1(CB 1), located on the surface of cells throughout the body, including in the central nervous system and immune system

[005] Consumption of high doses of THC may cause a variety of psychological reactions, such as anxiety, paranoia, delirium, ataxia, panic, fear, depression, impaired memory', and depersonalization. In addition, the body’s respiratory and vascular systems may be affected leading to tachycardia, postural hypotension, respiratory depression, and hyperkinesis.

[006] Different from inhaled THC, orally consumed THC through edibles is usually processed in the liver and converted into a metabolite called 11-hydroxy-THC. 11-hydroxy-THC can have significantly stronger psychological effects than THC, which is the underlying cause for a large number of cases related to over-consumption of THC through edibles.

[007] Given the increasingly prevalent uses of cannabis for medical and recreational purposes, there remains a need for novel therapeutic treatments for mitigating the undesirable effects caused by consumption of high doses of THC.

SUMMARY

[008] This Summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This Summary is not intended to identify key aspects or essential aspects of the claimed subject matter.

[009] In an aspect of the present disclosure, an antidote composition is disclosed. The antidote composition comprises: an amount of a cannabinoid; an amount of a surfactant; an amount of an oil; an amount of a co-surfactant, and an amount of distilled water. In embodiments, the cannabinoid comprises CBG. In embodiments, the cannabinoid comprises THCV. In alternate embodiments, the cannabinoid comprises any CB1 antagonist. In further alternate embodiments, the cannabinoid can be replaced with a non-cannabinoid CB1 antagonist. In embodiments, the composition is nanoemulsified. In embodiments, the cannabinoid is present in the composition at a concentration of about 0.1-30% of the composition. In further embodiments, the cannabinoid is present in the composition at a concentration of between about 0.2-20% of the composition. In further embodiments, the cannabinoid is present in the composition at a concentration of between about 0.4-10% of the composition. In further embodiments, the cannabinoid is present in the composition at a concentration of between about 1-3% of the composition. In further embodiments, the cannabinoid is present in the composition at a concentration of between about 1.2% and 2.2%. In further embodiments, the surfactant comprises Polysorbate 80 or a variant thereof. In further embodiments, the oil comprises olive oil or a variant thereof. In further embodiments, the co-surfactant comprises Span 60 or a variant thereof. In another aspect of the present disclosure, a method of treating a subject that has consumed a THC-containing product is disclosed. In certain embodiments, the method involves administering to the subject an effective amount of the antidote composition detailed herein. In embodiments, the antidote composition is administered to the subject from about 1 minute to about 12 hours after the THC-containing product. In further embodiments, the antidote composition is administered to the subject from about 30 minutes to about 8 hours after the THC-containing product. In further embodiments, the antidote composition is administered to the subject from about 1 hour to about 6 hours after the THC-containing product. In certain embodiments, the administering comprises at least two, or at least three, or at least four, or more than four administrations of the antidote composition.

[0010] In another aspect of the present disclosure, use of the antidote composition detailed herein is provided for treating a subject that has consumed a THC-containing product. In embodiments, the THC-containing product comprises an orally consumed, non-nano-emulsified edible.

[0011] All features of exemplary embodiments which are described in this disclosure and are not mutually exclusive can be combined with one another. Elements of one embodiment can be utilized in the other embodiments without further mention.

Other aspects and features of the present invention will become apparent to those ordinarily skilled in the art upon review of the following description of specific embodiments.

BRIEF DESCRIPTION OF THE FIGURES

[0012] In this Application:

[0013] FIG. 1 depicts an embodiment of the present disclosure detailing timing of administration of an antidote composition.

DETAILED DESCRIPTION

[0014] A detailed description of one or more embodiments of the invention is provided below along with any accompanying figures that illustrate the principles of the invention. The invention is described in connection with such embodiments, but the invention is not limited to any embodiment. Numerous specific details are set forth in the following description in order to provide a thorough understanding of the invention. These details are provided for the purpose of non-limiting examples and the invention may be practiced according to the claims without some or all of these specific details. For the purpose of clarity, technical material that is known in the technical fields related to the invention has not been described in detail so that the invention is not unnecessarily obscured. Overview

[0015] Disclosed herein are antidote compositions containing CBG and/or THCV that can counteract the effects of tetrahydrocannabinol (THC) and methods of using the same. In an aspect of the present disclosure, an antidote composition is disclosed that includes a nano-emulsified mixture of at least one cannabinoid, a surfactant, oil and water. In another aspect of the present disclosure, a method is disclosed whereby a subject, having previously orally consumed a THC-containing non-nanoemulsified edible, is administered an effective amount of a composition as described herein.

Definitions and Interpretation

[0016] Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those persons of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclature used in connection with, and techniques of, chemistry, plant biology, pharmacology and neurobiology described herein are those well-known and commonly used in the art. The methods and techniques of the present disclosure are generally performed according to conventional methods well- known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. If, and as applicable, any techniques (e.g., emulsification) are performed according to manufacturer's specifications, as commonly accomplished in the art or as otherwise described herein. The nomenclature used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art.

[0017] It will be understood by those persons of skill in the art that throughout the present specification, the term “a” used before a term encompasses embodiments containing one or more to what the term refers. It will also be understood by those of skill in the art that throughout the present specification, the term “comprising”, which is synonymous with “including,” “containing,” or “characterized by,” is inclusive or open-ended and does not exclude additional, un-recited elements or method steps.

[0018] If and as used herein, the terms “around”, “about” or “approximately ” shall generally mean within the error margin generally accepted in the art. Hence, numerical quantities given herein generally include such error margin such that the terms “around”, “about” or “approximately” can be inferred if not expressly stated.

[0019] Any and all references cited throughout the specification are hereby incorporated by reference in their entirety for all purposes.

[0020] Note that titles or subtitles may be used throughout the present disclosure for convenience of a reader, but in no way these should limit the scope of the invention. Moreover, certain theories may be proposed and disclosed herein; however, in no way they, whether they are right or wrong, should limit the scope of the invention so long as the invention is practiced according to the present disclosure without regard for any particular theory or scheme of action.

[0021] Other examples of implementations will become apparent to the reader in view of the teachings of the present description and as such, will not be further described here.

Description of Aspects and Embodiments of the Disclosure

[0022] Individuals consuming THC-containing products often experience psychoactive effects. However, an issue related to the consumption of THC-containing products, such as THC-containing edibles, is the uncontrollable and undesirable reactions resulting from the consumption of too much THC. Depending on a number of factors including the form of THC and its metabolites and an individual’s ability to process THC, the onset of the psychoactive effects of THC may be delayed until hours after consumption of THC. An individual not feeling the effects of THC may thus keep consuming THC-containing edibles leading to a buildup of THC in the small intestine before it enters the bloodstream A high concentration of THC may lead to a variety of undesirable reactions, including anxiety, paranoid, delirium, ataxia, panic, fear, depression, impaired memory, fear of dying, loss of control, hallucinations, shakiness/tremors, nausea, dry mouth, lack of self awareness, etc., all of which are effects of 11 -hydroxy -THC, a metabolite of THC, resulting from consumption of THC- containing edibles. It can be difficult for an individual to know the precise amount of THC-containing edibles that can be consumed without causing undesirable reactions.

[0023] The present disclosure is related to compositions and use of a cannabinoid- containing antidote that can counteract THC to prevent or eliminate its undesirable effects. Such antidote compositions are nano-emulsions administered before, coincident with, or after consumption of THC-containing products. The antidote compositions of the present disclosure are quickly absorbed by the human body to counteract the negative effects of THC.

[0024] In an aspect of the present disclosure, an antidote composition that can counteract the effects of THC is disclosed. In embodiments, the composition comprises a surfactant, an oil, water and a cannabinoid. In embodiments, the composition is in the form of a nano-emulsion.

[0025] In embodiments, the surfactant comprises a non-ionic surfactant, In embodiments, the surfactant comprises Polysorbate 80 (Tween 80). In embodiments, the surfactant comprises Span 60 (Sorbitan Monoester). In embodiments, the surfactant comprises a combination of Tween 80 and Sorbitan Monoester. In embodiments the surfactant comprises any one or any combination of lecithin, polyglycerols of fatty acid esters, and PEG, amongst others. In embodiments, the surfactant comprises any nonionic surfactant, or any combination of non-ionic surfactants. In embodiments, the hydrophilic/hydrophobic balance of the surfactant is between 10 and 14.

[0026] In embodiments, the oil in the composition comprises medium chain triglyceride (MCT), long chain triglyceride (LCT), or a combination thereof. In further embodiments, the oil in the composition comprises LCT. In embodiments, the oil in the composition comprises olive oil, hemp seed oil, coconut oil, sunflower oil, safflower oil, soybean oil, coconut oil, or a combination of thereof.

[0027] In embodiments, the water in the composition comprises purified water, distilled water, sterile water, or a combination of thereof.

[0028] In embodiments, the cannabinoid in the composition comprises an antagonist of a cannabinoid receptor. In embodiments, the cannabinoid receptor is cannabinoid receptor 1 (CB1). In embodiments, the cannabinoid in the composition comprises cannabigerol (CBG), tetrahydrocannabivarin (THCV), or a combination of thereof. In alternate embodiments, the cannabinoid comprises any CB1 antagonist. In further alternate embodiments, the cannabinoid can be replaced with a noncannabinoid CB1 antagonist.

[0029] In an aspect, a composition to make a nano-emulsion of CBG and THCV is provided. In embodiments, the composition comprises oil-soluble ingredients. In embodiments, the oil-soluble ingredients comprise any one or more of a carrier oil, an anti-oxidant, an oil-soluble surfactant, CBG, and THCV. In embodiments, the composition comprises water-soluble ingredients. In embodiments, the water-soluble ingredients comprise any one or more of a surfactant, pH balancers, and preservatives.

[0030] In embodiments, the nano-emulsion comprises stable particles between lOnm and 200nm. In embodiments, the nano-emulsion comprises stable particles less than 10nm In embodiments, the nano-emulsion comprises stable particles greater than 200nm In embodiments, the nano-emulsion comprises a particle size of less than

80nm.

[0031] In embodiments, the concentration of the nano-emulsion is up to 40mg/ml. In embodiments, the concentration of the nano-emulsion is greater than 40mg/ml. In embodiments, the nano-emulsion is stable in a pH range between 3 and 9. In embodiments, the nano-emulsion is stable at a pH below 3. In embodiments, the nanoemulsion is stable at a pH above 9.

[0032] In embodiments, the particles will have a zeta-potential of less than -30mv, which indicates the long-term stability of the nano-emulsion. In embodiments, the zeta-potential is greater than -30mv. In embodiments, the zeta potential is greater than 30mv.

[0033] In embodiments, the nano-emulsion is filtered to ensure a sterile product.

In embodiments, the nano-emulsion is filtered at about 0.22 micron.

[0034] In an aspect, a method of making a nano-emulsion is provided, In embodiments, the method comprises creating a homogenous mixture of oil-soluble ingredients. In embodiments, the oil-soluble ingredients comprise any one or more of a carrier oil, an anti-oxidant, an oil-soluble surfactant, CBG, and THCV. In embodiments, the method comprises creating a homogenous mixture of water-soluble ingredients. In embodiments, the water-soluble ingredients comprise any one or more of a surfactant, pH balancers, and preservatives. In embodiments, the method comprises mixing together the mixture of oil-soluble ingredients with the mixture of water-soluble ingredients.

[0035] In embodiments, the combined mixture of the oil-soluble and water-soluble ingredients is placed in either a high-pressure homogenizer, or an ultrasonic processor. In embodiments, this results in the creation of sufficient physical energy to break the oil phase into nano-scale particles which the surfactants will then stabilize to create a nano-emulsion formula.

[0036] In embodiments, the nano-emulsion of the composition comprises particles of 10-200 nanometers in size. In embodiments, the nano-emulsion of the composition is produced through a high energy method or a low energy method. In embodiments, the nano-emulsion of the composition is produced through a method, the method comprising the steps of ultra-sonication, high pressure homogenization, slow drip emulsification, or a combination of thereof. In embodiments, the nano-emulsion of the composition is produced through a method that includes the step of utilizing high pressure ultra-sonication.

[0037] In another aspect of the present disclosure, a method is disclosed. The method is directed to prevention or treatment of effects resulting from THC using at least one antidote composition disclosed herein.

[0038] In embodiments, a step in the method comprises identifying a subject in need of prevention or treatment of at least one effect resulting from THC. In embodiments, the subject is identified based on a subject’s expected consumption of a THC-containing product at a defined upcoming time and/or the subject is experiencing or is expected to experience at least one effect, including at least one negative effect, resulting from THC consumption. In embodiments, the at least one effect resulting from THC comprises anxiety, paranoid, delirium, ataxia, panic, fear, depression, impaired memory, fear of dying, loss of control, hallucinations, shakiness/tremors, nausea, dry mouth, lack of self awareness, or a combination of thereof. The THC- containing product can comprise a THC-containing dry flower decarboxylated or activated for oral consumption, a THC-containing oil, a THC-containing edible, or a combination of thereof.

[0039] In certain embodiments, a step in the method comprises administering to the subject a therapeutically effective amount of an antidote composition disclosed herein. The mode of administration can include oral consumption, a spray into the mouth or nasal passage for transmucosal absorption into the bloodstream. In alternate embodiments, the mode of administration can include direct injection.

[0040] Without limiting any of the foregoing, an antidote composition is disclosed herein. The antidote composition comprises: an amount of a cannabinoid; an amount of a surfactant; an amount of an oil; an amount of a co-surfactant; and an amount of distilled water. In embodiments, the cannabinoid comprises CBG. In embodiments, the cannabinoid comprises THCV. In embodiments, the composition is nano-emulsified. In embodiments, the cannabinoid is present in the composition at a concentration of 0.1-30% of the composition. In further embodiments, the cannabinoid is present in the composition at a concentration of between about 0.2-20% of the composition. In further embodiments, the cannabinoid is present in the composition at a concentration of between about 0.4-10% of the composition. In further embodiments, the cannabinoid is present in the composition at a concentration of between about 1-3% of the composition. In further embodiments, the surfactant comprises Polysorbate 80 or a variant thereof. In further embodiments, the oil comprises olive oil or a variant thereof. In further embodiments, the co-surfactant comprises Span 60 or a variant thereof.

[0041] In another aspect of the present disclosure, a method of treating a subject that has consumed a THC-containing product is disclosed. In certain embodiments, the method involves administering to the subject an effective amount of the antidote composition detailed herein. In embodiments, the antidote composition is administered to the subject from about 1 minute to about 12 hours after the THC-containing product. In further embodiments, the antidote composition is administered to the subject from about 30 minutes to about 8 hours after the THC-containing product. In further embodiments, the antidote composition is administered to the subject from about 1 hour to about 6 hours after the THC-containing product. In certain embodiments, the administering comprises at least two, or at least three, or at least four, or more than four administrations of the antidote composition.

[0042] In another aspect of the present disclosure, a human subject is selected to test the antidote composition. In embodiments, standard health measurements are obtained prior to the study (e.g., gender, height, weight, blood pressure, blood testing panel, neurological baseline testing, and behavioral baseline testing etc.).

[0043] In embodiments, the described efficacy test comprises a group of single clinical studies. In embodiments, in a single clinical study, the subject is provided with a defined amount of a THC-containing product for oral consumption. In embodiments, the amount of THC consumed by the subject is determined and measured prior to consumption. In embodiments, at a defined period of time coincident with or following consumption of the THC-containing product, the subject is provided with an amount of one antidote composition described herein. A representative timing schedule is outlined herein in FIG. 1.

[0044] In embodiments, at pre-determined intervals following the oral administration of the antidote composition, the human subject is examined for a panel of standard health measurements including but not limited to blood testing, neurological testing, and behavioral testing.

[0045] Data results from the above-described testing can be compared for the same individual who undergoes subsequent antidote challenges at different amounts and/or at different defined periods of time following the consumption of the THC-containing product. In embodiments, the data results will demonstrate optimal ranges of timing and antidote concentrations.

[0046] In another aspect of the present disclosure, use of the antidote composition detailed herein is provided for treating a subject that has consumed a THC-containing product.

[0047] EXAMPLES

[0048] Example 1: Antidote and Intoxicant Compositions

[0049] Antidote Compositions

[0050] An antidote composition is prepared by mixing the following ingredients: 2.184 grams of Polysorbate 80 (Tween 80, Co-surfactant), 0.336 gram of Span 60 (Sorbitan Monoester, Co-surfactant), 1.68 grams of olive oil, 32-65 grams of distilled water, and 0.84 grams of CBG. The mixture is then nano-emulsified into particles of 10-200 nanometers in size through ultra-sonication.

[0051] Another antidote composition is prepared by mixing the following ingredients: 6.552g Tween 80; 1.008g of Span 60; 6.72g of olive oil; 195g of water; and 2.52g of CBG distillate. This composition may be referred to as Batch 924.

[0052] Another antidote composition is prepared by mixing the following ingredients: 6.552g Tween 80, 1.008g Span 60; 6.72g olive oil; 195g of water; 1.68g CBG distillate; and 0.84g of THCV distillate. This composition may be referred to as Batch 930.

[0053] Another antidote composition is prepared by mixing the following ingredients: 6.552g Tween 80; L0080 Span; 6.72g olive oil; 125g water; 0.84g of CBG distillate; and 1.68g THCV distillate. This composition may be referred to as Batch 933.

[0054] Intoxicant Compositions

[0055] The following intoxicant compositions were prepared:

[0056] Batch 918 (cannabis distillate) is a hybrid cannabis extract that further contains: 1511mg of SureNano emulsifier (Caldic B.V.); preservatives; and 231.4ml of water. The total volume is 250ml.

[0057] Batch 909 (full spectrum cannabis extract) is an indica cannabis extract that further contains: 1782mg of SureNano emulsifier; preservatives; and 282.2ml of water. The total volume is 250ml.

[0058] Batch 926 (cannabis distillate) is a sativa cannabis extract that further contains: 2989mg of SureNano emulsifier; preservatives; and 463.1ml of water. The total volume is 500ml.

[0059] Batch 922 (decarboxylated shatter cannabis extract) is a sativa cannabis extract that contains: 1655mg of SureNano emulsifier; preservatives; and 229.7ml of water. The total volume is 250ml.

[0060] Example 2: Perception Analysis of Intoxication of Individuals that have Received THC

[0061] Experienced cannabis users participated in a cannabis trial in which the users self-administered a dose of THC cannabis extract. After self-administering the dose of THC cannabis extract, at various time points, the users self-reported their level of intoxication. The self-reported level of the intoxication was denoted on a scale of 1-10, with one (1) being the level that is closest to sober and ten (10) being the highest level of intoxication the user had experienced in the past twelve (12) months. The testing protocol was as follows:

[0062] Step 1: The user decides on a dose of THC.

[0063] Step 2: The user self-administers the dose of THC.

[0064] There were three (3) different sessions in which users administered the doses of THC: sessions G, H, and J. Below is the intoxicant composition each of the users self-administered in each of these sessions. [0065] Session G

[0066] In Session G, each of users JR and RL self-administered the intoxicant composition of Batch 909, as described herein. In Session g each of users MS and LM self-administered the intoxicant composition of Batch 918, as described herein.

[0067] Session H

[0068] In Session H, each of users MS and JR self-administered the intoxicate composition of Batch 926, as described herein.

[0069] Session J

[0070] In Session J, each of users MS, AC, and JR self-administered the intoxicant composition of Batch 922, as described herein.

[0071] Step 3: The user enters into an assessment form, her/his dose and the time the dose was self-administered.

[0072] Step 4: The batch information from which the dose derived is loaded into the assessment form

[0073] Step 5: The user tracks her/his level of intoxication at various time points.

[0074] Based on the denoted scale of 1-10, as described above, each user selfreported a time point when she/he had reached the peak intoxication level, after selfadministering the THC extract. Each user also self-reported a time point when her/his level of intoxication was at 20% of its peak, after self-administering the THC extract. This data point of 20% of peak intoxication is shown below in Table 1, in the column labeled “Baseline.”

[0075] In Session G: (i) individual JR achieved 20% of peak intoxication at 2:30 hours after receiving the intoxicant composition; (ii) individual RL achieved 20% of peak intoxication at 3:00 hours after receiving the intoxicant composition; (iii) individual MS achieved 20% of peak intoxication at 3:00 hours after receiving the intoxicant composition; and (iv) individual LM achieved 20% peak intoxication at 3:30 hours after receiving the intoxicant composition.

[0076] In Session H: (i) individual MS achieved 20% of peak intoxication at 3:00 hours after receiving the intoxicant composition; and (ii) individual JR achieved 20% of peak intoxication 2:30 hours after receiving the intoxicant composition. [0077] In Session J: (i) individual MS achieved 20% of peak intoxication at 3:15 hours after receiving the intoxicant composition; (ii) individual AC achieved 20% of peak intoxication at 3:30 hours after receiving the intoxicant compositions; and (iii) individual JR achieved 20% of peak intoxication at 3:00 hours after receiving the intoxicant composition.

Table 1

[0078] Example 3: Perception Analysis of Intoxication of Individuals that have Received THC and a CBG Antidote

[0079] Experienced cannabis users participated in a cannabis trial in which the users self-administered a dose of THC cannabis extract, and a CBG antidote. After self-administering the dose of THC cannabis extract, the users were administered a

CBG antidote. After receiving the CBG antidote, at various time points, the users selfreported level of the intoxication was denoted on a scale of 1-10, with one (1) being the level that is closest to sober and ten (10) being the highest level of intoxication the user had experienced in the past twelve (12) months. The testing protocol was as follows. [0080] Step 1: The user decides on a dose of THC.

[0081] Step 2: The user self-administers the dose of THC.

[0082] There were three (3) different sessions in which users self-administered the doses of THC: Sessions G, H, and J. Below, is the intoxicant composition each of the users self-administered in each of these sessions.

[0083] Session G

[0084] In Session G, each of users JR, RL, MS, and LM self-administered the antidote composition of Batch 924, as described herein.

[0085] Session H

[0086] In Session H, each of users MS and JR self-administered the antidote composition of Batch 930, as described herein.

[0087] Session J

[0088] In Session J, each of users MS, AC, and JR self-administered the antidote composition of Batch 933, as described herein.

[0089] Step 3: The user enters into an assessment form, her/his dose and the time the dose was self-administered.

[0090] Step 4: The batch information from which the dose derived is loaded into the assessment form

[0091] Step 5: Approximately sixty-five minutes after self-administeringthe dose of THC, the user is administered the CBG antidote or combined CBG/THCV antidote.

[0092] There were three (3) different sessions in which users self-administered the antidote compositions: Sessions: G, H, and J. Below, is the antidote composition each of the users self-administered in each of these sessions.

[0093] Session G

[0094] In Session G, each of users JR and RL self-administered the antidote composition of Batch 909, as described herein. In Session g each of users MS and LM self-administered the intoxicant composition of Batch 918, as described herein.

[0095] Session H [0096] In Session H, each of users MS and JR self-administered the intoxicate composition of Batch 926, as described herein.

[0097] Session J

[0098] In Session J, each of users MS, AS, and JR self-administered the intoxicant composition of Batch 922, as described herein.

[0099] Step 6: The user tracks her/his level of intoxication at various time points.

[00100] Based on the denoted scale of 1-10, as described above, each user selfreported a time point when she/he had reached the peak intoxication level, after selfadministering the THC extract. Each user also self-reported a time point when her/his level of intoxication was at 20% of its peak, after self-administering the THC extract. This data point of 20% of peak intoxication is shown above in Table 1, in the column labeled “With Anti-dote.”

[00101] In Session G: (i) individual JR achieved 20% of peak intoxication at 2:05 hours after receiving the intoxicant composition; (ii) individual RL achieved 20% of peak intoxication at 2:02 hours after receiving the intoxicant composition; (iii) individual MS achieved 20% of peak intoxication at 2:17 hours after receiving the intoxicant composition; and (iv) individual LM achieved 20% peak intoxication at 2:31 hours after receiving the intoxicant composition.

[00102] In Session G, this data demonstrates that, when administered the antidote composition, individuals JR, RL, MS, and LM reduced the time it took to get to 20% peak of intoxication by 25 minutes, 58 minutes, 43 minutes, and 59 minutes, respectively, relative to the baseline data in which individuals JR, RL, MS, and LM did not receive the antidote composition.

[00103] In Session H: (i) individual MS achieved 20% of peak intoxication at 2:07 hours after receiving the intoxicant composition; and (ii) individual JR achieved 20% of peak intoxication 2:03 hours after receiving the intoxicant composition.

[00104] In Session H, this data demonstrates that, when administered the antidote composition, individuals MS and JR reduced the time it took to get to 20% peak of intoxication by 53 minutes and 27 minutes respectively, relative to the baseline data in which individuals MS and JR did not receive the antidote composition. [00105] In Session J: (i) individual MS achieved 20% of peak intoxication at 2:08 hours after receiving the intoxicant composition; (ii) individual AC achieved 20% of peak intoxication at 2:05 hours after receiving the intoxicant compositions; and (iii) individual JR achieved 20% of peak intoxication at 1:55 hours after receiving the intoxicant composition.

[00106] In Session J, this data demonstrates that, when administered the antidote composition, individuals MS, AC, and JR reduced the time it took to get to 20% peak of intoxication by 1 hour and 7 minutes, 1 hour and 25 minutes, and 1 hour and 5 minutes, respectively, relative to the baseline data in which individuals MS, AC, and JR did not receive the antidote

Claims

CLAIMS WHAT IS CLAIMED IS:

1. An antidote composition comprising: an amount of a cannabinoid; an amount of a surfactant; an amount of an oil; an amount of a co-surfactant; and an amount of distilled water.

2. The antidote composition of claim 1, wherein the cannabinoid comprises CBG, THCV, or both.

3. The antidote composition of claim 1, wherein the composition is nano-emulsified.

4. The antidote composition of claim 2, wherein the cannabinoid is present in the composition at a concentration of between about 0.1-30% of the composition.

5. The antidote composition of claim 2, wherein the cannabinoid is present in the composition at a concentration of between about 0.2-20% of the composition.

6. The antidote composition of claim 2, wherein the cannabinoid is present in the composition at a concentration of between about 0.4-10% of the composition.

7. The antidote composition of claim 2, wherein the cannabinoid is present in the composition at a concentration of between about 1-3% of the composition.

8. The antidote composition of claim 1, wherein the surfactant comprises Polysorbate 80 or a variant thereof.

9. The antidote composition of claim 1, wherein the oil comprises a medium chain triglyceride, a long chain triglyceride or a variant thereof.

10. The antidote composition of claim 1, wherein the co-surfactant comprises Span 60 or a variant thereof.

11. A method of treating a subject that has consumed a THC-containing product, the method comprising administering to the subject an effective amount of the antidote composition of any one of claims 1-10.

12. The method of claim 11, wherein the antidote composition is administered to the subject from about 1 minute to about 12 hours after the THC-containing product.

13. The method of claim 11, wherein the antidote composition is administered to the subject from about 30 minutes to about 8 hours after the THC-containing product.

14. The method of claim 11, wherein the antidote composition is administered to the subject from about 1 hour to about 6 hours after the THC-containing product.

15. The method of claim 11, wherein the administering comprises at least two, or at least three, or at least four, or more than four administrations of the antidote composition.

16. Use of the antidote composition of any one of claims 1-10 for treating a subject that has consumed a THC-containing product.